Overview

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
BioNumerik Pharmaceuticals, Inc.
Collaborator:
Crown Bioscience
Treatments:
Camptothecin